

**CTAC**  
**Pancreatic Ductal Adenocarcinoma**  
**(PDAC) Progress Working Group**

**Interim Report**

James L. Abbruzzese

*July 8, 2015*

# Working Group's Purpose & Objectives

**The primary purpose of the PDAC Progress WG is to monitor NCI's progress of the Scientific Framework sent to Congress in February of 2014.**

The Working Group's main objectives are as follows:

- Assess NCI progress to date (*short term*)
- Provide recommendations for process of future annual assessment reports to CTAC (*intermediate term*)
- Review and update the scientific framework no later than 5 years after initial development (*long term*)
- Submit a report to Congress on the effectiveness of the scientific framework no later than 6 years after the initial development (*long term*)

# Scientific Framework's Four Initiatives & the Subgroups' Assignments

- Initiative 1: Understanding the Biological Relationship between PDAC and Diabetes Mellitus (DM)
  - Rachael Stolzenberg-Solomon\*, Jim Abbruzzese, Dana Andersen, Jane Holt, Murray Korc, Gloria Petersen, Sudhir Srivastava
- Initiative 2: Early Detection and Biomarkers
  - Gloria Petersen\*, James Abbruzzese, Tony Hollingsworth, Jane Holt, Alison Klein, Murray Korc, David Mankoff, Lynn Matrisian, Sheila Prindiville, Sudhir Srivastava
- Initiative 3: New Therapeutic Strategies in Immunotherapies
  - Elizabeth Jaffee\*, Jim Abbruzzese, Christine Alewine, Toby Hecht, Tony Hollingsworth, Jane Holt, Andrew Lowy
- Initiative 4: Development of RAS Therapeutics
  - Lynn Matrisian\*, Debbie Jaffe, Murray Korc, Andrew Lowy, Sudhir Srivastava, David Tuveson

\* Subgroups' Facilitators

# Scientific Framework's Implementation Process: Initial Impressions

- **All of the initiatives within the Scientific Framework are still relevant**
- **Initiative 1 (Relationship between PDAC and DM):**  
**Implementation progress is on target**
  - NIDDK/NCI RFA for a Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer released, grants submitted, review scheduled for Summer 2015, funding FY 2016
  - NIDDK/NIBIB meeting, “Advances in Biomedical Imaging, Bioengineering, and Related Technologies for the Development of Biomarkers of Pancreatic Disease” July 22, 2015
- **Initiative 2 (Early Detection and Biomarkers):**  
**Implementation progress is on target**
  - NCI PAR 15-289, “The Pancreatic Cancer Detection Consortium (U01) published June 30, 2015 ; <http://grants.nih.gov/grants/guide/pa-files/PAR-15-289.html>

# Scientific Framework's Implementation Process: Initial Impressions

- **Initiative 3 (Immunotherapy):**

Implementation plan needs further assessment

- Initiative would benefit from an additional meeting

- **Initiative 4 (Development of Ras Therapeutics):**

Implementation plan has been launched; however, additional information is needed to assess progress

- Learn more about FNLCR RAS project and relevance to PDAC

# Next Steps

- Webinar with the entire Working Group to finalize recommendations from the initial review – *July 16, 2015*
- Distribute working group report to CTAC – *November 4, 2015*

# Progress in PDAC WG Members

**Chair:** James Abbruzzese

**Members:**

Christine Alewine

Dana Andersen

Michael (Tony) Hollingsworth

Jane M. Holt

Elizabeth Jaffee

Alison Klein

Murray Korc

Andrew Lowy

David Mankoff

Lynn Matrisian

Gloria Petersen

Rachel Stolzenberg-Solomon

David Tuveson

**NIH Liaisons:**

Jeffrey Abrams

Dana Andersen

Amy Bulman

James Doroshow

Sarah Fabian

Samantha Finstad

Toby Hecht

Deborah Jaffe

LeeAnn Jensen

Bhupinder Mann

Sheila Prindiville

Sudhir Srivastava